Jianshi Technology-B (09877): The first group of subjects have been implanted with the LuX-ValvePlus transcatheter mitral valve replacement system, which is completed the pivotal trial approved by FDA.

Wisdom Financial News APP News, HealthTech-B (09877) announced that the company's independently developed transcatheter mitral valve replacement system LuX-ValvePlus has successfully completed the first group of participants implanted in the pivotal clinical trial approved by the Food and Drug Administration (FDA) in the United States in recent days, marking a breakthrough in the US registered clinical trial. This milestone represents another important achievement in the group's globalization strategy after obtaining EU MDR CE certification for the product.